Jiangsu Lianhuan Pharmaceutical (600513.SH) plans to sign a technology cooperation and development contract with Nanjing University to jointly research and develop anti-thrombotic small nucleic acid drugs.

Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company plans to sign a "Technology Cooperation and Development Contract" with Nanjing University, with the contract aiming to jointly develop anti-thrombotic small nucleic acid drugs. The total amount of the contract is 15 million yuan (including taxes), and according to the project development plan, the company will pay the cooperation fees to Nanjing University in installments as stipulated in the contract. In addition, after the successful development and listing of the target drug for sale, the company will pay royalties to Nanjing University based on a certain percentage of the annual sales revenue of the target drug for a period of 10 years. The announcement stated that the current domestic market for small nucleic acid drugs is mainly dominated by imported drugs, and there is a large development space in the domestic market compared to the global market. With the continuous increase in policy support and capital investment, the development of domestic small nucleic acid drugs is progressing rapidly. In the background of the booming global market and the upcoming rapid growth of the domestic market, the company plans to early layout in the field of small nucleic acid drugs, seize the market opportunity, and develop products that meet the needs of domestic patients based on a deep understanding of the domestic market demand. At the same time, this drug is deeply compatible with the company's strategic planning in the field of cardiovascular and cerebrovascular treatment, which is not only beneficial to enhancing the company's core competitiveness in research and development, but also can provide new momentum for the innovation drug product reserves, and promote the company to continue to deepen in this field. The purpose of this cooperation is to leverage Nanjing University's strong scientific research strength and previous research foundation in the field of nucleic acid drugs, combined with the company's industrialization and clinical development capabilities, to jointly promote the research and listing of innovative drugs.